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A B S T R A C T   
Diffuse large B-cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), is a highly 
heterogeneous and aggressive disease. Regardless of this heterogeneity, all patients receive the same first-line 
therapy, which fails in 30–40 % of patients, who are either refractory or relapse after remission. With the aim 
of stratifying patients to improve treatment outcome, different clinical and genetic biomarkers have been 
studied. The present systematic review aimed to identify somatic mutations that could serve as prognosis bio-
markers or as therapeutic target mutations in DLBCL. Regarding their role as prognostic markers, mutations in 
CD58 and TP53 seem the most promising predictors of poor outcome although the combination of different 
alterations and other prognostic factors could be a more powerful strategy. On the other hand, different ap-
proaches regarding targeted therapy have been proposed. Therefore, mutational analysis could help guide 
treatment choice in DLBCL yet further studies and clinical trials are needed.   
1. Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most common type of 
Non-Hodgkin lymphoma (NHL), accounting for 30 %–40 % of all newly 
diagnosed adult NHL cases (Siegel et al., 2017; Armitage et al., 2017). 
DLBCL is a high grade mature B-cell neoplasm that originates in lymph 
nodes or extranodal lymphoid tissue (Li et al., 2018). Even if it is 
considered as a single entity, it is a remarkably heterogeneous disease, 
with variable clinical features, morphological and genetic abnormal-
ities, and response to treatment (Swerdlow et al., 2016). 
Despite this heterogeneity, the combined chemotherapy of rituximab, 
cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is 
nowadays considered the standard first line therapy for all DLBCL pa-
tients (Kesavan et al., 2019). Although most patients with DLBCL treated 
with R-CHOP achieve complete remission, 30–40 % of patients are either 
refractory to this therapy or relapse after remission, requiring new 
therapeutic approaches (Coiffier et al., 2010; Coiffier, 2002; Sarkozy and 
Sehn, 2018). These relapsing or refractory patients present a poor prog-
nosis, therefore, the identification a priori of those patients who will not 
be cured by R-CHOP is one of the current challenges in the diagnosis of 
DLBCL. In this regard, considerable research has been performed in the 
last years with the aim of stratifying patients based on prognosis. 
So far, the International Prognostic Index (IPI) is one of the most 
important prognostic tools for survival prediction. This score stratifies 
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patients according to intrinsic factors (age, performance status) and the 
extent and aggressiveness of the disease (stage, presence of extranodal 
infiltration, lactate dehydrogenase levels) (Project IN-HsLPF, 1993). 
However, these clinical parameters do not address the underlying bio-
logical heterogeneity of DLBCL. Consequently, some limitations remain, 
such as poor characterization and huge heterogeneity, resulting in dif-
ficulties to predict survival; in fact, the utility of IPI in the era of 
immunochemotherapy has not been established, and the subsequent 
revisions that have appeared (the R-IPI and the NCCN-IPI) also fail to 
adequately identify extremely high-risk groups response precisely 
enough to design risk adapted therapies (Wight et al., 2018). 
In recent years the application of gene expression profiling (GEP) to 
the study of DLBCL was a major advance which further clarified DLBCL 
heterogeneity and provided a rationale for subdividing cases into 
groups. The most popular system separates cases of DLBCL according to 
cell-of-origin into germinal center B-cell like (GCB) and activated B-cell 
like (ABC) subtypes, the latter having a worse overall prognosis (Ali-
zadeh et al., 2000). Nevertheless, about 10–15 % of cases cannot be 
classified into any of these two groups. Moreover, although cell-of-origin 
is useful for predicting outcome, GCB and ABC subtypes remain very 
heterogeneous with better and worse prognostic subsets within each 
group (Li et al., 2018). 
Finally, the application of next generation sequencing (NGS) tech-
nologies in DLBCL has allowed the identification of numerous genetic 
abnormalities in these neoplasms that can be used as predictive or 
prognostic biomarkers to assess the risk of treatment failure better than 
traditional tools (Chapuy et al., 2018; Schmitz et al., 2018; Wright et al., 
2020). NGS studies have also found some possible actionable mutations 
and have confirmed that the ABC and GCB subtypes present character-
istic mutational profiles that may explain the difference in gene 
expression and clinical outcomes (Miao et al., 2019). In spite of these 
advances, clinical and therapeutic implications of most mutations in 
DLBCL remain unknown. Therefore, in-depth knowledge of the genetic 
landscape in DLBCL is needed to identify prognostic and actionable 
mutations that would allow to perform a risk-adapted guided thera-
peutic approach. 
The present review aimed to identify a panel of somatic mutations 
that could be used as prognosis biomarkers or as therapeutic target 
mutations in DLBCL through a systematic search of the literature. 
2. Materials and methods 
2.1. Search strategy 
We performed an exhaustive systematic search in Pubmed database 
(https://www.ncbi.nlm.nih.gov/pubmed) following the PRISMA pro-
tocol to identify studies that analyzed the prognostic/therapeutic value 
of coding somatic mutations in DLBCL. We used the keywords and 
subject terms “(somatic mutations OR genetic alterations) AND (diffuse 
large B cell lymphoma OR DLBCL)” for articles published until 16th of 
December 2019. All references within the identified studies were then 
reviewed in order to identify additional matches. 
2.2. Inclusion and exclusion criteria 
Articles were included if they were independent original studies that 
supplied information on somatic mutations as prognosis biomarkers or 
therapeutic target mutations in DLBCL in human population. Articles 
not published in English, reviews and meta-analyses, letters, comments, 
methodological articles and studies which used nonstandard oncological 
treatment were excluded. Additionally, studies that analyzed germinal 
mutations, non-coding somatic mutations, mitochondrial mutations, 
IGH-VDJ rearrangements (or other rearrangements), or investigated 
other diseases or species were also excluded. Each eligible manuscript 
was assessed independently by three researchers (GM, MLS, PA). Dis-
agreements were solved by consensus. 
2.3. Data extraction 
Data extracted from each study included: studied genes, mutations 
detected, pathway in which they were implicated, mutation frequency, 
sample size, sample characteristics (age, de novo/secondary, received 
treatment, IPI score, subtype ABC vs GCB), implications of the mutations 
in DLBCL prognosis (overall survival [OS], progression free survival 
[PFS], lymphoma-specific survival [LSS], disease-specific survival 
[DSS], event-free survival [EFS], time-to-progression [TTP], complete 
remission [CR] or relapse percentage) and whether they were thera-
peutic target mutations. In order to define associations between somatic 
mutations and DLBCL outcome, a p value < 0.05 in association with any 
of the considered endpoints of prognosis was considered. 
3. Results 
The original search provided a total of 575 records. Out of them, 492 
were discarded after abstract revision because they did not meet the 
required inclusion criteria. The full texts of the remaining 83 studies 
were examined in detail. Further 55 articles were excluded because they 
were not focused on somatic mutations as prognosis biomarkers or 
therapeutic targets in DLBCL. After reviewing the references of the 
identified articles, 14 additional studies were included. Finally, a total of 
42 articles investigating the role of somatic mutations as prognosis 
biomarkers or therapeutic targets in DLBCL were included (Fig. 1). All of 
them except one considered mutations in DLBCL as prognosis bio-
markers (Chapuy et al., 2018; Schmitz et al., 2018; Leroy et al., 2002; 
Kerbauy et al., 2004; Iqbal et al., 2007; Young et al., 2008, 2007; Zai-
nuddin et al., 2009; Liu et al., 2010; Stefancikova et al., 2011; Schuetz 
et al., 2012; Bu et al., 2012; Xu-Monette et al., 2012; Schif et al., 2013; 
Trinh et al., 2013; Morin et al., 2013; Bertrand et al., 2013; Asmar et al., 
2014; Kristensen et al., 2014; Fernández-Rodríguez et al., 2014; Novak 
et al., 2015; Cen et al., 2015; Schiefer et al., 2015; Dubois et al., 2016; 
Xu-Monette et al., 2016; Juskevicius et al., 2016; Xia et al., 2017; Cao 
et al., 2016; Dubois et al., 2017; Xu et al., 2017; Juskevicius et al., 2017; 
Ennishi et al., 2017; Zlamalikova et al., 2017; Karube et al., 2018; Reddy 
et al., 2017; Voropaeva et al., 2019; Ramis-Zaldivar et al., 2020; Bolen 
et al., 2020; Arthur et al., 2018; Møller et al., 2000; Grønbaek et al., 
2000), while 8 articles also defined mutations found in DLBCL patients 
as therapeutic targets or analyzed the frequency of somatic mutations 
previously defined as therapeutic targets (Bertrand et al., 2013; Schiefer 
et al., 2015; Dubois et al., 2016, 2017; Xu et al., 2017; Ennishi et al., 
2017; Karube et al., 2018; Dubois et al., 2015). 
3.1. Prognosis biomarkers 
A total of 41 studies analyzing gene mutations as prognosis bio-
markers in DLBCL were identified in the systematic search (Supple-
mentary Table S1). The vast majority (n = 38) studied the prognostic 
value of mutations in a unique gene, while 10 of them and other 3 
additional studies (n = 13) analyzed mutations in a group of genes, in a 
specific pathway or cluster, or evaluated the combination of gene mu-
tations with diverse genetic alterations (Chapuy et al., 2018; Schmitz 
et al., 2018; Stefancikova et al., 2011; Asmar et al., 2014; Kristensen 
et al., 2014; Schiefer et al., 2015; Dubois et al., 2017; Xu et al., 2017; 
Juskevicius et al., 2017; Karube et al., 2018; Reddy et al., 2017; Bolen 
et al., 2020; Grønbaek et al., 2000). A subset of studies differentiated 
DLBCL subtypes when analyzing the impact on prognosis of mutations 
identified. On the one hand, 15 studies specifically showed results in 
ABC or non-GC subtype (Chapuy et al., 2018; Schmitz et al., 2018; Iqbal 
et al., 2007; Young et al., 2008, 2007; Zainuddin et al., 2009; Xu-Mo-
nette et al., 2012; Cen et al., 2015; Dubois et al., 2016; Xu-Monette et al., 
2016; Xia et al., 2017; Dubois et al., 2017; Ennishi et al., 2017; Reddy 
et al., 2017; Bolen et al., 2020), from which 10 focused exclusively on 
single gene mutations (Iqbal et al., 2007; Young et al., 2008, 2007; 
Zainuddin et al., 2009; Xu-Monette et al., 2012; Cen et al., 2015; Dubois 
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et al., 2016; Xu-Monette et al., 2016; Xia et al., 2017; Dubois et al., 2017; 
Ennishi et al., 2017; Bolen et al., 2020) and three exclusively on the 
combination with other genetic alterations (Chapuy et al., 2018; 
Schmitz et al., 2018; Dubois et al., 2017; Reddy et al., 2017; Bolen et al., 
2020) and the remaining two articles studied both (Dubois et al., 2017; 
Bolen et al., 2020). On the other hand, 15 studies displayed results in 
GCB subgroup (Chapuy et al., 2018; Schmitz et al., 2018; Iqbal et al., 
2007; Young et al., 2008, 2007; Zainuddin et al., 2009; Xu-Monette 
et al., 2012; Morin et al., 2013; Xia et al., 2017; Juskevicius et al., 2017; 
Ennishi et al., 2017; Reddy et al., 2017; Bolen et al., 2020; Arthur et al., 
2018; Xu-Monette et al., 2015), from which 11 referred solely to single 
gene mutations (Iqbal et al., 2007; Young et al., 2008, 2007; Zainuddin 
et al., 2009; Xu-Monette et al., 2012; Morin et al., 2013; Xu-Monette 
et al., 2016; Xia et al., 2017; Juskevicius et al., 2017; Ennishi et al., 2017; 
Bolen et al., 2020; Arthur et al., 2018), three focused solely on the 
combination of gene mutations with other genetic alterations (Chapuy 
et al., 2018; Schmitz et al., 2018; Reddy et al., 2017; Bolen et al., 2020) 
and one article analyzed both of them (Bolen et al., 2020). 
3.1.1. Single gene mutations 
Considering DLBCL globally, 36 genes were found to be significantly 
associated with outcome (Table 1). In most cases, the relationship be-
tween gene mutations and prognosis was analyzed by a single study, 
finding an association with worse outcome in 19 genes (HERC2, 
KIAA1614, ODZ3/TENM3, C10orf12, DIAPH2, SEC14L5, BAI1, SDK2, 
TRIM2, MYO19, FBLN2, COL12A1, ALDH3A2, KIF1C, HEPH, FGFRL1, 
KLHL14, ZFAT and SETD5) (Novak et al., 2015; Reddy et al., 2017) and 
with better outcome in two genes (NF1, HRAS) (Reddy et al., 2017). The 
other 15 genes were examined by at least two studies, all of them dis-
playing discordant results: worse outcome- or non-significant results 
(CD58, BCL2, MYD88, KLHL6, FOXO1, MYC, CD79B, PIM1, CDKN2A, 
PAX5, TP53); better outcome- or non-significant results (EZH2, BCL6, 
SOCS1); and conflicting results (better, worse or no-significant differ-
ences in outcome) (SGK1). For 13 of these genes the majority of studies 
performed did not show any association with prognosis: BCL2 (7 out of 9 
studies) (Schuetz et al., 2012; Novak et al., 2015; Cao et al., 2016; 
Juskevicius et al., 2017; Ennishi et al., 2017; Karube et al., 2018; Reddy 
et al., 2017), BCL6 (4 out of 5) (Juskevicius et al., 2016; Cao et al., 2016; 
Karube et al., 2018; Reddy et al., 2017), CD79B (6 out of 7) (Novak et al., 
2015; Juskevicius et al., 2016; Cao et al., 2016; Juskevicius et al., 2017; 
Karube et al., 2018; Bolen et al., 2020), CDKN2A (2 out of 3) (Juskevi-
cius et al., 2016; Karube et al., 2018), EZH2 (5 out of 6) (Juskevicius 
et al., 2016; Cao et al., 2016; Juskevicius et al., 2017; Karube et al., 
2018; Bolen et al., 2020), KLHL6 (2 out of 3) (Juskevicius et al., 2016; 
Reddy et al., 2017), MYC (7 out of 9) (Novak et al., 2015; Xu-Monette 
et al., 2016; Juskevicius et al., 2016; Cao et al., 2016; Juskevicius et al., 
2017; Ennishi et al., 2017; Karube et al., 2018), MYD88 (7 out of 9) 
(Novak et al., 2015; Juskevicius et al., 2016; Cao et al., 2016; Xu et al., 
2017; Juskevicius et al., 2017; Karube et al., 2018; Reddy et al., 2017; 
Bolen et al., 2020), PIM1 (6 out of 7) (Novak et al., 2015; Juskevicius 
et al., 2016; Cao et al., 2016; Juskevicius et al., 2017; Karube et al., 
2018; Bolen et al., 2020), SOCS1 (4 out of 5) (Schif et al., 2013; Jus-
kevicius et al., 2017; Karube et al., 2018; Reddy et al., 2017), PAX5 (1 
out of 2) (Juskevicius et al., 2016), FOXO1 (3 out of 5) (Juskevicius 
et al., 2016; Karube et al., 2018; Reddy et al., 2017), and SGK1 (2 out of 
4) (Juskevicius et al., 2016, 2017). Among the lacking two genes, TP53 
was the most often analyzed: 10 articles showed statistically significant 
association with adverse prognosis (Leroy et al., 2002; Kerbauy et al., 
2004; Young et al., 2008, 2007; Zainuddin et al., 2009; Liu et al., 2010; 
Xu-Monette et al., 2012; Cao et al., 2016; Zlamalikova et al., 2017; 
Ramis-Zaldivar et al., 2020), while 10 studies had non-significant results 
(Asmar et al., 2014; Kristensen et al., 2014; Novak et al., 2015; Juske-
vicius et al., 2016, 2017; Karube et al., 2018; Reddy et al., 2017; Vor-
opaeva et al., 2019; Bolen et al., 2020; Møller et al., 2000). Besides, two 
additional studies explored not only mutations but also deletions in 
TP53 as prognosis biomarkers, finding that the presence of any of these 
was a signal of unfavorable prognosis in R-CHOP treated patients (Ste-
fancikova et al., 2011; Schiefer et al., 2015). In addition, CD58 was the 
only other gene among those studied by more than 3 studies for which at 
least half of the studies supported an association with outcome (2 out of 
4 found association with worse outcome) (Novak et al., 2015; Cao et al., 
2016; Karube et al., 2018; Reddy et al., 2017). 
Regarding DLBCL subtypes, 6 genes were found to show significant 
association with outcome in ABC/non-GC patients: BCL6 (Iqbal et al., 
2007) and CD79B (Dubois et al., 2017) correlated with favorable 
prognosis; and GNA13 (Dubois et al., 2016), PRDM1 (Xia et al., 2017), 
Fig. 1. Flowchart of study selection.  
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Table 1 
Mutations in single genes associated with prognosis in DLBCL.  




Apoptosis and autophagy 
MYC 
4.5− 5.5 ↓ (Reddy et al., 2017; Ramis-Zaldivar et al., 2020) 
5.3− 33.3 n.s. 
(Novak et al., 2015; Juskevicius et al., 2016; Cao et al., 2016; Juskevicius 
et al., 2017; Ennishi et al., 2017; Karube et al., 2018); (Xu-Monette et al., 
2016)* 
BCL2 
8− 10.3 ↓ (Juskevicius et al., 2016); (Bolen et al., 2020)* 
4.1− 37 n.s. (Schuetz et al., 2012; Novak et al., 2015; Cao et al., 2016; Juskevicius et al., 
2017; Ennishi et al., 2017; Karube et al., 2018; Reddy et al., 2017) 
B-cell recept/ (BCR) /Toll-like 




10 ↓ (Fernández-Rodríguez et al., 2014)* 
6.6 n.s. (Juskevicius et al., 2017) 
MYD88 11.8− 24 n.s. 
(Novak et al., 2015; Juskevicius et al., 2016; Cao et al., 2016; Karube et al., 
2018; Reddy et al., 2017; Bolen et al., 2020) 
CD79B 
5.0 ↓ (Reddy et al., 2017) 
5.3− 25.6 n.s. 
(Novak et al., 2015; Juskevicius et al., 2016; Cao et al., 2016; Juskevicius 
et al., 2017; Karube et al., 2018; Bolen et al., 2020) 
KLHL6 8 ↓ (Karube et al., 2018)* 
6.8− 7.7 n.s. (Juskevicius et al., 2016; Reddy et al., 2017) 
B-cell diffferentiation 
BCL6 
61 ↑ (Iqbal et al., 2007) 
4.7− 6 n.s. (Cao et al., 2016; Karube et al., 2018; Reddy et al., 2017) 
0 n.a. (Juskevicius et al., 2016) 
PAX5 
5.7 ↓ (Reddy et al., 2017) 
0 n.a. (Juskevicius et al., 2016) 
DNA damage 
TP53 
8.9− 23 ↓ 
(Leroy et al., 2002; Kerbauy et al., 2004; Young et al., 2008; Liu et al., 2010;  
Xu-Monette et al., 2012; Cao et al., 2016)*; (Young et al., 2007; Zainuddin 
et al., 2009; Zlamalikova et al., 2017; Ramis-Zaldivar et al., 2020) 
12.3− 25.6 n.s. 
(Kristensen et al., 2014; Novak et al., 2015; Juskevicius et al., 2016, 2017;  
Karube et al., 2018; Reddy et al., 2017); (Asmar et al., 2014; Voropaeva et al., 
2019; Møller et al., 2000)* ; (Bolen et al., 2020)* †
TP53 mut/ 
del 28.3− 31.7 ↓ (Schiefer et al., 2015)*; (Stefancikova et al., 2011) (treated with R-CHOP) 
CDKN2A 
9.08 ↓ (Reddy et al., 2017) 
4 n.s. (Karube et al., 2018) 
0 n.a. (Juskevicius et al., 2016) 
ADGRB1 5.9 ↓ (Novak et al., 2015) 
Epigenome/Chromatin modifier EZH2 
6.0 ↑ (Reddy et al., 2017) 
3.1− 13.2 n.s. 
(Cao et al., 2016; Juskevicius et al., 2017; Karube et al., 2018; Bolen et al., 
2020) 
0 n.a. (Juskevicius et al., 2016) 
SETD5 3.2 ↓ (Reddy et al., 2017) 
Extracellular matrix organization FBLN2 5.9 ↓ (Novak et al., 2015) 
COL12A1 5.9 ↓ (Novak et al., 2015) 
Immune response 
CD58 
2.8− 5.1 ↓ (Cao et al., 2016)*; (Reddy et al., 2017) 
5.9− 10.7 n.s. (Novak et al., 2015; Karube et al., 2018) 
HERC2 15.7 ↓ (Novak et al., 2015) 
TRIM2 5.9 ↓ (Novak et al., 2015) 
JAK-STAT pathway 
SOCS1 
12.8 ↑ (Juskevicius et al., 2016) 
9.7− 27.6 n.s. (Schif et al., 2013; Juskevicius et al., 2017)*; (Karube et al., 2018; Reddy 
et al., 2017) 
PIM1 
17.3 ↓ (Reddy et al., 2017) 
9.2− 30.8 n.s. 
(Novak et al., 2015; Juskevicius et al., 2016; Cao et al., 2016; Juskevicius 
et al., 2017; Karube et al., 2018; Bolen et al., 2020) 
MAP kinase signaling 
HRAS 1.9 ↑ (Reddy et al., 2017) 
NF1 3.4 ↑ (Reddy et al., 2017) 
NOTCH pathway SGK1 
7 ↓ (Karube et al., 2018) * 
7.7 ↑ (Reddy et al., 2017) 
5.3− 10.7 n.s. (Juskevicius et al., 2016, 2017) 
PI3K-AKT signaling FOXO1 
3.9− 8.6 ↓ (Trinh et al., 2013)*; (Novak et al., 2015) 
2.6− 10.7 n.s. (Juskevicius et al., 2016; Karube et al., 2018; Reddy et al., 2017) 
Rho GTPases signaling DIAPH2 5.9 ↓ (Novak et al., 2015) 
Tryptophan Metabolism ALDH3A2 5.9 ↓ (Novak et al., 2015) 
Transmembrane transport of small 
molecules 
HEPH 5.9 ↓ (Novak et al., 2015) 
Vesicle-mediated transport KIF1C 5.9 ↓ (Novak et al., 2015) 
VEGF signaling pathway FGFRL1 5.9 ↓ (Novak et al., 2015) 
– ZFAT 4.0 ↓ (Reddy et al., 2017) 
– KLHL14 5.5 ↓ (Reddy et al., 2017) 
– TENM3 7.8 ↓ (Novak et al., 2015) 
– KIAA1614 9.8 ↓ (Novak et al., 2015) 
– SEC14L5 5.9 ↓ (Novak et al., 2015) 
– SDK2 5.9 ↓ (Novak et al., 2015) 
– MYO19 5.9 ↓ (Novak et al., 2015) 
– LCOR 5.9 ↓ (Novak et al., 2015) 
B-cell diffferentiation 
BCL6 44 ↑ (Iqbal et al., 2007) 
PRDM1 26 ↓ (Xia et al., 2017) 
(continued on next page) 
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TP53 (Xu-Monette et al., 2012) and TNFAIP3 (Dubois et al., 2016) 
correlated with worse prognosis. However, TP53, CD79B and TNFAIP3 
genes, which were the only ones analyzed by more than one study, 
showed also no significant results: TP53 was not associated with prog-
nosis in four out of five articles (Young et al., 2008, 2007; Zainuddin 
et al., 2009; Bolen et al., 2020) and both CD79B (Bolen et al., 2020) and 
TNFAIP3 (Cen et al., 2015) did not show any association in one out of 
two articles. Considering GCB patients, two genes were associated with 
unfavorable outcome, TP53 in three out of five articles (Young et al., 
2008; Zainuddin et al., 2009; Xu-Monette et al., 2012) and ATM in one 
study (Juskevicius et al., 2017). 
3.1.2. Pathway or multiple-gene related mutations 
Thirteen articles described a significant association between somatic 
mutations in multiple-genes/specific pathway or the combinations of 
different mutations with other genetic alterations and survival in DLBCL 
(Table 2). For instance, two studies found that patients with disruption 
of CDKN2A and p53 pathways concurrently had significantly shorter 
survival than patients with disruption of one or no pathways (Karube 
et al., 2018; Grønbaek et al., 2000). Other work, analyzing not only 
genetic TP53 mutations but also epigenetic variations, discovered that 
the double hit MIR34A methylation and TP53 mutation was an inde-
pendent factor for survival in DLBCL patients, even after correction for 
multivariate analysis; however, neither methylation of MIR34A nor 
TP53 mutation alone influenced survival (Asmar et al., 2014). Another 
study found that TNFR pathway was more frequently mutated in pa-
tients who did not achieve complete remission after treatment, while 
BCR pathway mutations were associated with shorter PFS in the sub-
group of patients who reached complete remission (Xu et al., 2017). 
Finally, CREBBP and/or EP300 mutations were associated with poor 
survival in a multivariate analysis (Juskevicius et al., 2017); even 
though neither of these genes had been associated individually (Juske-
vicius et al., 2016; Cao et al., 2016; Juskevicius et al., 2017; Karube 
et al., 2018; Reddy et al., 2017). 
On the other hand, Schmitz et al. described diverse subtypes of 
DLBCL based on their genomic alterations: EZB subtype, characterized 
by EZH2 mutations and/or BCL2 translocations, and BN2 genetic sub-
type, characterized by BCL6 fusions or/and NOTCH2 mutations, dis-
played improved survival; N1 subtype, characterized by NOTCH1 
mutations, and MCD subtype, characterized by MYD88 L265 P + CD79B 
mutations, showed deteriorated survival (Schmitz et al., 2018). How-
ever, Bolen et al. tried to validate these classifications using an 
approximation of EZB, BN2, N1 and MCD clusters using each cluster’s 
founder alterations (EZH2 or BCL2; BCL6 or NOTCH2; NOTCH1; and 
MYD88 L265 P or CD79B, respectively), but they did not observe any 
difference in prognosis among any of the four mutational subgroups 
(Bolen et al., 2020). Likewise, Chapuy et al. described 6 different clus-
ters (C0-C5) based on their genetic alterations and established a prog-
nosis based on this clustering: C3 (defined by GCB-DLBCLs with BCL2 
structural variants and alterations of PTEN and epigenetic enzymes) and 
C5 (major components being BCL2 gain, concordant MYD88 L265 
P/CD79B mutations, and additional mutations of ETV6, PIM1, GRHPR, 
TBL1XR1, and BTG1) presented a poorer prognosis; while C1 (defined by 
ABC-DLBCLs with genetic features of an extrafollicular, possibly mar-
ginal zone origin) and C4 (defined by GCB-DLBCLs with distinct alter-
ations in BCR/PI3K, JAK/STAT, and BRAF pathway components and 
multiple histones) and C0 (not otherwise defined) clusters having a 
better prognosis. Besides, they discovered that C3/C5 and C2 groups 
separately were significantly associated with worse outcome comparing 
to C0/C1/C4 patients (Chapuy et al., 2018). Later, Bolen et al. applied 
the non-negative matrix factorization (NMF) clustering algorithm to the 
set of mutations overlapping with those reported by Chapuy et al. to 
recreate the Chapuy classification, resulting in six clusters G0-G5 
equivalent to C0-C6 clusters of Chapuy’s study respectively. G2, G3 
and G5 (equivalent to Chapuy’s C2, C3 and C5) showed significantly 
worse prognosis when compared with clusters G0, G1 and G4 (Chapuy’s 
C0, C1 and C4, respectively) (Bolen et al., 2020). 
Finally, Reddy et al. proposed a genomic risk model in DLBCL based 
on combinations of genetic and expression features and validated their 
predictive modeling approach using an independent test set (20 % of the 
data), which was able to distinguish patients with high versus low risk of 
death. In fact, it was also able to discern patients with significantly 
distinct outcomes within risk groups that are known to influence sur-
vival: cell of origin, double expression of MYC and BCL2, and IPI (Reddy 
et al., 2017). Bolen et al. also used this genomic risk model to test its 
utility as prognosis tool but after correcting for COO, the model was not 
significantly associated with prognosis (Bolen et al., 2020). 
3.2. Therapeutic targets 
We identified eight articles proposing a series of 29 genes as thera-
peutic targets of drugs that could potentially be used in DLBCL (Bertrand 
et al., 2013; Schiefer et al., 2015; Dubois et al., 2016, 2017; Xu et al., 
2017; Ennishi et al., 2017; Karube et al., 2018; Dubois et al., 2015) 
(Table 3). In order to identify therapeutic targets for the identified 
genomic alterations, different strategies were followed: seven studies 
proposed candidate drugs against somatic mutations based on previous 
literature, whereas one study performed in silico analyses using the 
software Cancer Genome Interpreter (https://www.cancergenomeinter 
preter.org/) (Karube et al., 2018). From the 29 proposed genes, 16 
presented only one associated candidate type of drugs while 13 were 
described as targets of diverse drugs. Similarly, some of the proposed 
drugs were linked to more than one actionable gene alteration. 
Among them, three combinations of mutated genes and targeted 
drugs were proposed by more than two studies: three studies proposed 
BCL2 inhibitors for BCL2 mutants (Schiefer et al., 2015; Dubois et al., 
2016; Ennishi et al., 2017), three studies proposed EZH2 inhibitors for 
EZH2 mutants (Dubois et al., 2016; Karube et al., 2018; Dubois et al., 
Table 1 (continued ) 






BCR signaling pathway CD79B 
28.1 ↑ (Dubois et al., 2017) 
25 n.s. (Bolen et al., 2020) 
DNA damage TP53 
17.8 ↓ (Xu-Monette et al., 2012) 
14.5− 24 n.s. (Young et al., 2007; Zainuddin et al., 2009; Bolen et al., 2020); (Young et al., 
2008)* 
NF-κB Signaling TNFAIP3 11.1 ↓ (Dubois et al., 2016) 
†
29.5 n.s. (Cen et al., 2015) 
PI3K-AKT signaling GNA13 9.3 ↓ (Dubois et al., 2016) †
GCB-DLBCL DNA damage TP53 
10.6− 34 ↓ (Zainuddin et al., 2009; Xu-Monette et al., 2012); (Young et al., 2008)* 
19− 30 n.s. (Young et al., 2007; Bolen et al., 2020) 
ATM 15.6 ↓ (Juskevicius et al., 2017) 
n.s.: non-significant; n.a.: not available. 
* Multivariate analysis. 
† FDH correction. 
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Table 2 
Pathway / multiple-gene related mutations associated with prognosis in DLBCL.  




TP53 mut/CDKN2A del 35.3 ↓ (Karube et al., 
2018) * 
TP53 mut/ CDKN2A del /CDKN2A meth 38.2 ↓ 
(Grønbaek et al., 
2000) 
MIR34A meth/TP53 mut 6 ↓ 
(Asmar et al., 
2014)* 
B-cell recept/ (BCR) /Toll-like 
recept/ (BCR-TLR) signaling 
pathway 
CARD11/LYN/CD79A/CD79B 25.5 ↓ (Xu et al., 2017) 
MYD88 18.2 ↓ (Xu et al., 2017) 
TRAF2/TNFAIP3 14.5 ↓ (Xu et al., 2017) 
NOTCH signaling NOTCH2/ NOTCH1/ FBXW7/ SGK1 19.3 ↓ 
(Karube et al., 
2018) * 
Epigenome/ Chromatin modifier CREBBP mut/EP300 mut 18 ↓ 
(Juskevicius et al., 
2017)* 
DLBCL ABC JAK-STAT + NF-κB MYD88 L265 P + CD79B (vs MYD88 L265 P + CD79B no mut) 14.9 ↑ (Dubois et al., 
2017)  
EZB subtype EZH2 mut/BCL2 transl 
12 ↑ (Schmitz et al., 
2018) 
20 n.s. # (Bolen et al., 
2020) 
N1 subtype NOTCH1 mut 
3.3 ↓ 
(Schmitz et al., 
2018) 
2.4 n.s.# 
(Bolen et al., 
2020) 
BN2 subtype BCL6 fusions/NOTCH2 mut 
17.1 ↑ (Schmitz et al., 
2018) 
11.4 n.s. # (Bolen et al., 
2020) 
MCD subtype MYD88 L265 P/CD79B mut 
12.4 ↓ 
(Schmitz et al., 
2018) 
13.1 n.s. # 
(Bolen et al., 
2020)  
Reddy-Genomic risk model 
High risk (HR): MYC & MYC-high / ZFAT / ABC DLBCL & KLHL14 / BCL2-high & BIRC6 
/ MYC-high & CDKN2A / BCL2-high & GNA13 / BCL2-high & TP53 / SETD5 / BCL2- 
high & PIM1 & MYD88 / MYC-high & CARD11 / MYC-high & ABC DLBCL & MLL2 / 
MYC-high & BCL2-high & HIST1H1E / CD79B & PIM1 / BCL2-high & ABC DLBCL & 
HIST1H1E / BCL2-high & MCL1 / ABC DLBCL & SPEN / KLHL14 & PIM1, MSH2, NC/1, 
ABC DLBCL & CDKN2A, BCL2-high & MYD88 & MLL2, DNMT3A / BCL2-high & MLL3 / 
BCL2-high & BTG1 Low Risk (LR): CHD1, GCB DLBCL & B2M / SGK1 / GNAS / ABC 
DLBCL & ZEB2, GCB DLBCL & MT/ / ABC DLBCL & DDX10 / ABC DLBCL & CREBBP, 
ABC DLBCL & ATM, TNFRSF14 & MLL2, GCB DLBCL & EZH2 / NF1 / GCB DLBCL & 
MYD88 / GCB DLBCL & ARID5B / GCB DLBCL & CD70 
52.9− 56.3 
(HR) ↓ 
(Reddy et al., 
2017) 
29.4 (HR) n.s. & 
(Bolen et al., 
2020)  
C0 cluster without defined genetic drivers 4% ↑ 
(Chapuy et al., 
2018) * 
C1 cluster BCL6 / BCL10 / TNFAIP3 / UBE2A / CD70/ B2M / ZEB2 / NOTCH2 / TMEM30A / FAS / 
TP63 / ZEB2 / HLA-B / SPEN /PD-L1-ligands / CN gain 5q/p 
21 % ↑ (Chapuy et al., 
2018) * 
C2 cluster TP53 alt / CNAs 21.2 % n.s. (Chapuy et al., 
2018) * 
C3 cluster 
BCL2 alt / CREBBP/ EZH2 / KMT2D / TNFRSF14 / HVCN1 / IRF8 / GNA13 / MEF2B / 
PTEN alt 18.1 % ↓ 
(Chapuy et al., 
2018) * 
C4 cluster 
SGK1 / HIST1H1E / NFKBIE / BRAF / CD38 / NFKBIA / CD58 / HIST1H2BC / STAT3 / 
HIST1H1D / HIST1H1B / ETS1 / TOX / HIST1H2AM / HIST1H2BK / RHOA / ACTB / 
LTB / SF3B1 / CARD11 / HIST1H2AC 
16.9 % ↑ 
(Chapuy et al., 
2018) * 
C5 cluster 
CN-gain 18p/q / CN-gain 3q/p / CD79B / MYD88 / ETV6 / PIM1 / CN-loss 17q25.1 / 
TBL1XR1 / CN-gain 19q13,42 / GRHPR / ZC3H12A / CN-loss 19p13.2 /CN-gain 19q / 
HLA-A / BTG1 / PRDM1 
21 % ↓ 
(Chapuy et al., 
2018) * 
C3/C5 vs C0/C1/C4   ↓ 
(Chapuy et al., 
2018) * 
C2 vs C0/C1/C4   ↓ 
(Chapuy et al., 
2018) * 
G2/3/5 vs G0/1/4$   ↓ (Bolen et al., 
2020)  
* Multivariate analysis; n.s.: non-significant. 
& Mutational model generated by Reddy et al modified. 
# Clusters were approximated using the seed mutations: EZB - EZH2 / BCL2; BN2 - BCL6 / NOTCH2; N1 - NOTCH1; MCD - MYD88, L265 P / CD79B. 
$ Clusters were approximated by application of non-negative matrix fact/ization (NMF) to the GOYA FMI dataset and selecting five clusters (G1-G5). 
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Table 3 
Targeted drugs and actionable mutations in DLBCL.  
Gene Mutation Drug Reference 
APC – Tankyrase inhibitor (Karube et al., 2018) 
ARID1A – EZH2 inhibitor (Karube et al., 2018)  
– PARP inhibitor (Karube et al., 2018) 
BCL2 – BCL2 inhibitor (BH3 mimetics) (Dubois et al., 2016)  
– BCL2 inhibitor (BH3 mimetics) (Schiefer et al., 
2015)  
– BCL2 inhibitor (venetoclax) (Ennishi et al., 
2017) 
BRAF inframe deletions (L485X, P490X) Pan-RAF inhibitor (Karube et al., 2018)  
– BRAF inhibitor (Dubois et al., 2016) 
BRCA2 – PARP inhibitor (Olaparib, Rucaparib) (Karube et al., 2018)  
– PD1 Antibody (Karube et al., 2018)  
– Platinum (Chemotherapy) (Karube et al., 2018) 
CARD11/TNFAIP – Decreased activity of ibrutinib and sotrastaurin 
(PKCi) 
(Dubois et al., 2016) 
CD70 – Anti-CD70 antibody/ CD70specific T-cells (Bertrand et al., 
2013) 
CD79B – BTK inhibitor (ibrutinib) (Karube et al., 2018)  
– BTK inhibitor (Dubois et al., 2016) 
CDKN2A – CDK4/6 inhibitor (Karube et al., 2018)  
– AURKA-VEGF inhibitor (Ilorasertib) (Karube et al., 2018) 
CREBBP – HDAC inhibitor (Dubois et al., 2016) 
EP300 – HDAC inhibitor (Dubois et al., 2016) 
EZH2 Y641X, A677X EZH2 inhibitor (EPZ-005,687) (Karube et al., 2018)  
Y641 F,A677X EZH2 inhibitor (EPZ-005,687, EPZ-6438) (Karube et al., 2018)  
– EZH2 inhibitor (EPZ-6438) (Karube et al., 2018)  
– EZH2 inhibitor (Dubois et al., 2016)  
EZH2 + mutant-like IHC methylation profiles EZH2 inhibitor (Dubois et al., 2015) 
IRF4 – Lenalidomide (Dubois et al., 2016) 
KIT D816Y, D816 F, D816V BCR-ABL inhibitor 2nd gen (Dasatinib) (Karube et al., 2018) 
KRAS – CDK4/6 inhibitor (Karube et al., 2018)  
– Defactinib (Pan-kinase inhibitor) (Karube et al., 2018)  
– FAK inhibitor (Karube et al., 2018)  
– FAS inhibitor (Karube et al., 2018)  
– HSP90 inhibitor (in combination) (Karube et al., 2018)  
– JAK/TBK1/IKKε inhibitor (Karube et al., 2018)  
– MEK inhibitor (Selumetinib) (Karube et al., 2018)  
– PI3K pathway inhibitor (Karube et al., 2018)  
– PI3K pathway inhibitor + MAPK pathway 
inhibitor 
(Karube et al., 2018) 
MTOR L1460 P, S2215Y, R2505P Sirolimus (MTOR inhibitor) (Karube et al., 2018) 
MYC – BET inhibitor (Dubois et al., 2016)  
– MYC inhibitor (Ennishi et al., 
2017) 
MYD88 – IRAK1/4 inhibitor (Xu et al., 2017)  
– BTK inhibitor (ibrutinib) (Dubois et al., 2016)  
– BTK inhibitor (ibrutinib) (Xu et al., 2017) 
MYD88+CD79B MYD88 (L265 P) + CD79B oncogenic mutation BTK inhibitor (ibrutinib) (Karube et al., 2018)  
– BTK inhibitor (ibrutinib) (Dubois et al., 2016) 
MYD88 +no alterations in CARD11/ 
TNFAIP3 
– BTK inhibitor (ibrutinib) (Dubois et al., 2017) 
NOTCH1 activating mutation (missense in TAD or truncating in Cterm 
domain) 
Gamma secretase inhibitor (Karube et al., 2018)  
activating mutation (missense in TAD or truncating in Cterm 
domain) 
NOTCH1 inhibitor (OMP-52M51) (Karube et al., 2018)  
– NOTCH inhibitor (Dubois et al., 2016) 
NOTCH2 activating mutation (missense in TAD or truncating in Cterm 
domain) 
Gamma secretase inhibitor (Mk-0752) (Karube et al., 2018)  
activating mutation (missense in TAD or truncating in Cterm 
domain) 
NOTCH2 inhibitor (OMP-59R5) (Karube et al., 2018)  
– NOTCH inhibitor (Dubois et al., 2016) 
PIK3CA – PI3K pathway inhibitor (Karube et al., 2018)  
– PIK3CA inhibitor (Karube et al., 2018) 
PIK3R1 – AKT inhibitor (Karube et al., 2018) 
PIM1 – PIM inhibitor (Dubois et al., 2016) 
SOCS1 – JAK/STAT inhibitor (Dubois et al., 2016) 
STAT6 – JAK/STAT inhibitor (Dubois et al., 2016) 
TNFAIP3 – NFKB inhibitor (Dubois et al., 2016)  
– proteasome inhibitors (bortezomib and 
carfilzomib) 
(Xu et al., 2017) 
TP53 R248Q, R175H HSP90 inhibitor (Karube et al., 2018)  
– ATR inhibitor (AZD6738) (Karube et al., 2018)  
– WEE1 inhibitor (MK-1775) (Karube et al., 2018)  
– Amylin analogue (Pramlintide) (Karube et al., 2018) 
XPO1 – SINE (Dubois et al., 2016)  
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2015), and four studies proposed the BTK inhibitor ibrutinib for MYD88 
mutants (Dubois et al., 2016, 2017; Xu et al., 2017; Karube et al., 2018). 
4. Discussion 
The heterogeneity of DLBCL confers variable clinical outcome to 
patients with DLBCL treated with R-CHOP. Consequently, the identifi-
cation of more efficient prognostic markers and therapeutic targets is 
necessary. To date, many genetic alterations have been involved in the 
pathogenesis of DLBCL. Nevertheless, few of those alterations have been 
described as prognostic markers or therapeutic targets. Therefore, this 
systematic review focuses on key mutations that could help elucidate the 
prognosis of DLBCL or individualize the treatment. This search identi-
fied 40 single genes and different combinations associated with prog-
nosis and 29 genes that could serve as therapeutic targets. 
4.1. Prognostic value of genetic alterations 
Considering the studies that analyzed single genes in all DLBCL 
patients as a whole, most mutated genes with significant prognostic 
implications (n = 21) were studied only once and, thus, these results 
need validation before their real value as prognostic factors can be 
confirmed. Among these, HERC2 mutations, which presented a high 
frequency among DLBCL patients (15.7 % of patients) and were asso-
ciated with worse outcome (Novak et al., 2015), deserve special 
mention. HERC2 leads to the recruitment of BRCA1 at DNA damage 
sites (Bekker-Jensen et al., 2010) for its repair, and high HERC2 
expression was found to be associated with worse prognosis in other 
neoplasms, such as non-small-cell lung cancer (Bonanno et al., 2016). 
Therefore, although further studies are needed, it should be considered 
as potential prognosis biomarker. 
The other 15 genes were studied at least twice. However, all of them 
presented discordant results among studies. In fact, available data as a 
whole seems to support a lack of prognostic significance for 13 of these 
genes due to the fact that the majority of studies performed did not show 
any association with prognosis: BCL2, BCL6, CD79B, CDKN2A, EZH2, 
KLHL6, MYC, MYD88, PIM1, SOCS1, PAX5, FOXO1, and SGK1. How-
ever, some aspects must be taken into consideration. For instance, the 
very diverse mutational frequency of BCL6 among studies is very 
remarkable, ranging from 0 %–6 % in no-significant studies (Juskevicius 
et al., 2016; Cao et al., 2016; Karube et al., 2018; Reddy et al., 2017) to 
61 % in the article where it was associated with outcome (Iqbal et al., 
2007), which could be contributing to the discordance in results. Even 
though Igbal et al. included 8.6 % of patients classified as PMBL, which 
are characterized by higher mutational frequency of BCL6, the fre-
quency of BCL6 mutations in the rest of subgroups was also higher than 
in the other studies. On the other hand, PAX5 mutations were only 
studied by two different studies, one showed association with worse 
outcome (Reddy et al., 2017), whereas the other one did not. Never-
theless, the latter was performed in a much smaller sample (n = 39 vs 
1001) and its mutational frequency was of 0%, explaining the lack of 
significance. Similarly, CDKN2A was only studied in three studies and 
being found associated with prognosis in the study with the largest 
population (n = 1001). Given its relatively low frequency of mutation 
(0–9.08 %), a high number of patients may be needed in order to detect 
its effect on prognosis. Therefore, further studies would be needed to 
confirm or discard their role in prognosis. 
Other factors to take into account are that differences on prognosis 
significance among studies may also lay in the different prognosis end-
points analyzed in each study or in the specific effect of each mutation 
on the functionality of the gene. In this line, although Xu-Monette et al. 
confirmed the lack of association of MYC mutations with prognosis 
taking into account all mutations overall, they described a group of 
mutations (S62, S67, P79, R83, A141, S175 and A 185 mutations) 
associated with favorable prognosis, and others (missense mutations at 
T58 and F138, which were involved in increased Myc stability, gain-of- 
function and reduced response to apoptosis in vitro) with significantly 
poorer survival. In addition, MYD88 L265 P was associated with unfa-
vorable prognosis in a multivariate analysis (Fernández-Rodríguez et al., 
2014) and, although this association was not confirmed in another study 
(Juskevicius et al., 2017), it could be attributed to the low number of 
MYD88 L265P-mutated cases (n = 5) included in the survival analysis. 
On the other hand, CD58 and TP53 are the only two genes among 
those studied by more than 3 studies for which at least half of the studies 
support an association with outcome. The remaining genes not 
mentioned above, were only found associated with prognosis in one or 
two studies and were found not associated in more studies, including 
analyses with very large sample sizes. Thus, this two are the most 
promising single genes for prognostic stratification. 
First, CD58 activates T cells and natural killer (NK) cells by its 
adhesion to CD2 receptor on their surface. Mutations in CD58 inducing a 
decrease in CD58 protein levels impede cytolysis of DLBCL cells (Miao 
et al., 2019). Prognostic significance of CD58 mutations was studied by 4 
articles, two of them finding association with worse prognosis (Cao 
et al., 2016; Reddy et al., 2017), one of them even independently of 
other prognostic factors (Cao et al., 2016). The negative studies, how-
ever, were performed using smaller sample sizes, which could serve as 
explanation for not finding significant results (Novak et al., 2015; Kar-
ube et al., 2018). Therefore, detecting CD58 mutations could lead to 
better stratification of patients with worse prognosis for whom immu-
notherapy could become an alternative therapy. 
Finally, TP53, which is a tumor suppressor gene and regulates cell 
division by keeping cells from growing and proliferating in an uncon-
trolled way, was the most frequently studied gene in the articles 
included in this review. Loss of function of TP53 either by mutations or 
deletion is a well-known prognostic biomarker in many hematological 
neoplasms, and in some cases such as in acute myeloid leukemia and 
chronic lymphocytic leukemia, the loss of TP53 activity can guide 
treatment strategy (Campo et al., 2018). However, the prognostic value 
of TP53 mutations in DLBCL is still controversial: some articles indicated 
negative prognostic implications (Leroy et al., 2002; Kerbauy et al., 
2004; Young et al., 2008, 2007; Zainuddin et al., 2009; Liu et al., 2010; 
Xu-Monette et al., 2012; Cao et al., 2016; Zlamalikova et al., 2017; 
Ramis-Zaldivar et al., 2020), while others found no association (Asmar 
et al., 2014; Kristensen et al., 2014; Novak et al., 2015; Juskevicius et al., 
2016, 2017; Karube et al., 2018; Reddy et al., 2017; Voropaeva et al., 
2019; Bolen et al., 2020; Møller et al., 2000). It must be noted, though, 
that in some of these studies presenting no association, TP53 mutations 
showed a non-significant tendency to lower PFS or OS or were associ-
ated with outcome in univariate analysis but not in the multivariate 
analysis. In addition, a combination of TP53 mutations and deletions 
was also associated with unfavorable prognosis in two additional studies 
(Stefancikova et al., 2011; Schiefer et al., 2015), further supporting a 
possible prognostic value. Furthermore, given that different mutations 
were identified in different studies, discrepancies in results among 
studies suggest that different mutations in TP53 could have different 
effects on DLBCL, as proposed above for other genes. In fact, mutations 
located in DNA binding domains have been suggested to have a higher 
effect on survival than mutations in other regions (Young et al., 2008, 
2007; Karube et al., 2018), which would support this hypothesis. 
Considering DLBCL subtypes separately, TP53 was the unique gene 
with significant results studied by two or more studies, and it was 
associated with poor prognosis in GCB-DLBCL patients in 3/5 studies 
(Young et al., 2008; Zainuddin et al., 2009; Xu-Monette et al., 2012), 
whereas it showed no significant association in ABC or non-GC patients 
in 4/5 studies (Young et al., 2008, 2007; Zainuddin et al., 2009; Bolen 
et al., 2020); suggesting that, it could have a dual behavior depending on 
the DLBCL subtype, which could be explained by the different mecha-
nisms underlying each subtype. 
On the other hand, thirteen studies described significant associations 
between survival and somatic mutations or combinations of mutations and 
other alterations in multiple genes or specific pathways. In fact, taking into 
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account the heterogeneity observed in DLBCL, it seems unlikely that 
mutations in a single gene justify such variability, and an integrative 
analysis of the mutational status of different genes and pathways could 
improve the prognostic classification and the treatment choice. 
Some studies combined pairs of genes or single pathways but, 
interestingly, a group of studies incorporated information about diverse 
genetic aberrations and other prognostic factors into prognostic models 
of DLBCL that could stratify patients into differentiated groups (Chapuy 
et al., 2018; Schmitz et al., 2018; Reddy et al., 2017; Bolen et al., 2020). 
While most combinations have only been analyzed once, it is 
remarkable that some genes were included in several combinations. For 
instance, TP53 was studied in combination with CDKN2A, methylation 
of MIR34A or within the p16INK4a/ARF-p53 pathway, the different 
combinations reflecting a negative effect on prognosis (Asmar et al., 
2014; Karube et al., 2018; Grønbaek et al., 2000). CREBBP was also 
studied in combination with EP300 and in different molecular sub-
groups, the combinations being associated with poorer prognosis. This is 
of note regarding that mutations in CREBBP alone have not been 
significantly associated with outcome, which supports the idea that 
combinations of mutations have a greater power to predict patients’ 
outcome. On the other hand, while mutations in NOTCH pathway were 
associated with a worse outcome, in the different molecular subgroups 
mutations in NOTCH1 are usually incorporated into the high risk groups 
while mutations in NOTCH2 are included in groups of better prognosis, 
which suggests that mutations in different genes of the same pathway do 
not necessarily need to have the same effect. 
Among the proposed prognostic models, Chapuy’s classification was 
the one with the most robust evidence to be a useful tool, because it was 
first established that C3/C5 and C2 groups individually were signifi-
cantly associated with worse outcome in comparison with C0/C1/C4 
patients (Chapuy et al., 2018), and later their homologous G3 (enrich-
ment of BCL2 and CREBBP) /G5 (enrichment of ABC subset) /G2 
(enrichment of TP53 and REL) patients had worse outcome in compar-
ison with G0/G1/G4 (Bolen et al., 2020). It is remarkable that G5 is 
characterized by enrichment of ABC subtype, which are generally 
related to worse outcome. 
In conclusion, the incorporation of genetic alterations as prognosis 
markers into risk stratification systems could improve the classification 
of patients. However, further studies are required to validate the prog-
nostic implication of the reported genetic alterations. 
4.2. Genetic alterations as therapeutic targets 
Nowadays, there is a wide range of available drugs that can target 
specific genes or pathways. Therefore, the introduction of drugs that 
target pathways of relevance in DLBCL could be of relevance in order to 
improve the outcome of the disease. In this context, we have identified 
eight articles proposing pairs of drugs and their target genes and alter-
ations that could serve as new therapeutic strategies in DLBCL. 
Among them, three combinations of mutated genes and targeted 
drugs were proposed by more than two studies: three studies proposed 
BCL2 inhibitors for BCL2 mutants (Schiefer et al., 2015; Dubois et al., 
2016; Ennishi et al., 2017), three studies proposed EZH2 inhibitors for 
EZH2 mutants (Dubois et al., 2016; Karube et al., 2018; Dubois et al., 
2015), and four studies proposed the BTK inhibitor ibrutinib for MYD88 
mutants (Dubois et al., 2016, 2017; Xu et al., 2017; Karube et al., 2018). 
Regarding BCL inhibitors, BH3 mimetics was proposed as a possible 
therapeutic option for DLBCL patients. In fact, the BH3 domain of BCL2 
was shown to be unaffected by the mutations detected in DLBCL patients 
(Dubois et al., 2016), indicating that BH3 mimetic activity would not be 
hampered. One of those BH3 mimetic drugs, venetoclax, was shown to 
have substantial antitumor activity in patients with B-cell lymphomas in 
a recently published study (Roberts et al., 2016). 
On the other hand, phosphorylation of Bruton’s tyrosine kinase 
(BTK) promotes nuclear factor kappa B (NF-κB) activity, which is a 
hallmark of ABC-DLBCL. Ibrutinib binds irreversibly to BTK and blocks 
its kinase activity. Consequently, it was hypothesized that ABC-DLBCL 
tumors, the viability of which depends on NF-KB activity, would 
respond to ibrutinib. Different studies have shown that, even though 
ABC DLBCL responds better to ibrutinib than GCB tumors regardless of 
the mutational landscape (Wilson et al., 2015), the presence of muta-
tions in MYD88 and/or CD79B increase its activity, while CARD11 and 
TNFAIP3 mutations impact negatively on its therapeutic activity 
(Fernández-Rodríguez et al., 2014; Dubois et al., 2016, 2017; Wilson 
et al., 2015). While CD79B and MYD88 are upstream of BTK in the NF-κB 
signaling pathway, CARD11 and TNFAIP3 are downstream effectors; 
thus, DLBCL with activating mutations in genes encoding for proteins 
with an effect downstream of BTK could escape the effect of its inhibitor, 
ibrutinib. Therefore, combinations of mutations in different genes 
should be considered before assigning a specific targeted therapy. 
Recurrent somatic mutations inducing a gain-of-function of EZH2 
have been identified in DLBCL, and some cell lines with those mutations 
depend on EZH2’s higher catalytic activity for proliferation (Dubois 
et al., 2015). Therefore, EZH2 inhibitors could lead to a blockade in 
uncontrolled proliferation when that kind of mutations are present in 
DLBCL, presenting an alternative therapeutic option. It must be noted 
that, depending on the specific mutations identified in EZH2, different 
drugs are available (Karube et al., 2018; Dubois et al., 2015; Italiano 
et al., 2018; Knutson et al., 2014, 2012). 
Finally, in the last years more therapeutic opportunities have been 
described based on other genetic aberrations. For instance, drugs tar-
geting B-cell receptor–dependent NF-KB activation (e.g., inhibitors of 
BTK and protein kinase C beta) for BN2 and MCD DLBCL subtypes; 
immune-checkpoint inhibitors for N1 subtype; or inhibitors of B-cell 
receptor proximal signaling (e.g., spleen tyrosine kinase [SYK] in-
hibitors) or the downstream PI3 kinase pathway for lesions that alter 
negative regulators of B-cell receptor signaling or the B-cell receptor 
subunits CD79A and CD79B (Schmitz et al., 2018). 
4.3. Limitations 
It must be noted that this review presented several limitations. First of 
all, the number of studies that analyzed some specific genes and com-
binations was limited and, therefore, reaching reliable conclusions was 
complicated, further data being necessary. Besides, the clinical and 
methodological heterogeneity among studies must be considered. 
Focusing on sample size heterogeneity, it varied from 30 (Ramis-Zaldivar 
et al., 2020) to 1001 patients (Reddy et al., 2017). Statistical significance 
is strongly influenced by the sample size, and an effect that fails to be 
significant at a specified alpha level in a small sample could be significant 
in larger samples. Therefore, the genes determined as non-prognosis 
biomarkers by studies with bigger samples are more reliable than those 
of smaller samples. In addition, it must be taken into account that the 
percentage of GCB/ABC subtype and IPI-group was different in each 
study (Table S1), and these differences could also influence divergence in 
prognosis. Moreover, the treatment schemas used also varied and the 
gene mutations pointed out as prognosis biomarkers, could really be 
predictive for only specific treatments. Furthermore, the included studies 
presented methodological heterogeneity in the way the mutations were 
analyzed and in the phenotypes analyzed, which could lead to differences 
in results. In addition, it is possible that some additional articles have 
been missed by our search strategy. Furthermore, there is a tendency to 
prioritize statistically significant results for publication, which may lead 
to a bias and an underrepresentation of non-significant results. 
Looking into the future of the field, it must also be taken into 
consideration that, currently, most studies are centered in coding genes, 
which made these the focus of the present review. Remarkably, non- 
coding regions are gaining relevance as biomarkers in different cancer 
settings. Interestingly, as mentioned above, the combination of MIR34A 
methylation and TP53 mutation was an independent factor for survival 
in DLBCL patients (Asmar et al., 2014) and miR34 mimics have been 
proposed as alternative therapeutic options in p53 deficient cancer cells 
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(Ji et al., 2008). Therefore, existing evidence suggests that a deep 
analysis of alterations in non-coding regions could further improve the 
establishment of biomarkers and therapeutic options in DLBCL. 
5. Conclusions and future direction 
DLBCL is a very complex disease and additional markers are needed 
for stratification of patients according to their prognosis and for the 
identification of novel therapeutic strategies. In this line, in this sys-
tematic review, we have deepened in the role of somatic mutations. 
Regarding their role as prognostic markers, most genes have been 
studied in a limited number of studies, further research being necessary 
to reach conclusions. Focusing on those genes that have been more 
extensively studied, mutations in CD58 and TP53 seem the most prom-
ising predictors of poor outcome. Remarkably, the combination of 
different alterations and other prognostic factors for the establishment 
of subtypes appears to be a powerful strategy. On the other hand, with 
the expansion of targeted therapeutics, more and more mutations are 
being described as targets or as predictors of response to specific drugs. 
Of note, EZH2 inhibitors have been proposed as candidate drug against 
mutated EZH2 DLBCL and ibrutinib for DLBCL with mutations in BCR, 
CD79B and/or MYD88 in different studies. We can conclude that this is a 
very promising field of study, which could help guide treatment choice 
in DLBCL yet further studies and clinical trials are needed. 
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